Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
EAHAD 2026: Nine-Year Outcomes of Gene Therapy
February 2026
Nine-year data show sustained safety and reduced bleeding after gene therapy in haemophilia B, although enrichment for full viral capsids did not deliver clear clinical advantages.
Read more
26 Jun 2015
Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses…
26 Jun 2015
The crucial roles of GFI1B in platelet development
The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result in the…
26 Jun 2015
Pacritinib therapy led to symptom improvement in myelofibrosis
The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more…
26 Jun 2015
Treatment and outcome of CML patients from the EUTOS population-based registry
The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML).
26 Jun 2015
Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL
n a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination…
26 Jun 2015
Adding elotuzumab to standard treatment for myeloma reduced disease progression
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory…
12 May 2015
Dr Keith Stewart chairs a discussion on tumour biology-guided treatment for multiple myeloma
At the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Gareth Morgan (University of Arkansas…
12 May 2015
Clinical significance of progenitor cells in multiple myeloma
Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) and Prof Gareth…
Loading posts...
« Previous
1
…
94
95
96
97
98
…
100
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View